175 related articles for article (PubMed ID: 35158847)
1. TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma.
Toda S; Sato S; Saito N; Sekihara K; Matsui A; Murayama D; Nakayama H; Suganuma N; Okubo Y; Hayashi H; Iwasaki H; Miyagi Y; Hoshino D
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158847
[TBL] [Abstract][Full Text] [Related]
2. TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
Seok JY; Astvatsaturyan K; Peralta-Venturina M; Lai J; Fan X
Int J Surg Pathol; 2021 Jun; 29(4):368-377. PubMed ID: 33289434
[TBL] [Abstract][Full Text] [Related]
3. TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma.
Brunelli M; Gobbo S; Malpeli G; Sirgiovanni G; Caserta C; Munari E; Francesconi S; Caliò A; Martignoni G; Cimadamore A; Veccia A; Antonelli A; Tucci M; Pierconti F; Hattab IM; Eccher A; Ascani S; Milella M; Buffoni L; Cheng L; Bracarda S
Pathologica; 2024 Feb; 116(1):55-61. PubMed ID: 38482675
[TBL] [Abstract][Full Text] [Related]
4. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.
Ghali F; Vakar-Lopez F; Roudier MP; Garcia J; Arora S; Cheng HH; Schweizer MT; Haffner MC; Lee JK; Yu EY; Grivas P; Montgomery B; Hsieh AC; Wright JL; Lam HM
Clin Genitourin Cancer; 2023 Dec; 21(6):669-678. PubMed ID: 37344281
[TBL] [Abstract][Full Text] [Related]
5. Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants.
Fan Y; Li Q; Shen Q; Liu Z; Zhang Z; Hu S; Yu W; He Z; He Q; Zhang Q
Front Oncol; 2022; 12():858865. PubMed ID: 35515131
[TBL] [Abstract][Full Text] [Related]
6. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.
Simms A; Jacob RP; Cohen C; Siddiqui MT
Diagn Cytopathol; 2016 Jan; 44(1):26-31. PubMed ID: 26481593
[TBL] [Abstract][Full Text] [Related]
7. B7-H3 and ICAM-1 are potentially therapeutic targets for thyroid carcinoma.
Song P; Xu Y; Ye G
Diagn Pathol; 2024 Jun; 19(1):77. PubMed ID: 38858715
[TBL] [Abstract][Full Text] [Related]
8. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.
Yun JY; Kim YA; Choe JY; Min H; Lee KS; Jung Y; Oh S; Kim JE
J Clin Pathol; 2014 Feb; 67(2):125-33. PubMed ID: 23986551
[TBL] [Abstract][Full Text] [Related]
9. PAX8 expression in anaplastic thyroid carcinoma is less than those reported in early studies: a multi-institutional study of 182 cases using the monoclonal antibody MRQ-50.
Lai WA; Hang JF; Liu CY; Bai Y; Liu Z; Gu H; Hong S; Pyo JY; Jung CK; Kakudo K; Bychkov A
Virchows Arch; 2020 Mar; 476(3):431-437. PubMed ID: 31732814
[TBL] [Abstract][Full Text] [Related]
10. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
11. Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma.
Jung CW; Han KH; Seol H; Park S; Koh JS; Lee SS; Kim MJ; Choi IJ; Myung JK
Int J Clin Exp Pathol; 2015; 8(1):560-8. PubMed ID: 25755746
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
13. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
Murtezaoglu AR; Gucer H
Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974
[TBL] [Abstract][Full Text] [Related]
14. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
15. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
16. TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study.
Addati T; Achille G; Centrone M; Petroni S; Popescu O; Russo S; Grammatica L; Simone G
Cytopathology; 2015 Oct; 26(5):303-11. PubMed ID: 25164548
[TBL] [Abstract][Full Text] [Related]
17. Long Non-coding RNA Expression in Anaplastic Thyroid Carcinomas.
Wang Y; Hardin H; Chu YH; Esbona K; Zhang R; Lloyd RV
Endocr Pathol; 2019 Dec; 30(4):262-269. PubMed ID: 31468286
[TBL] [Abstract][Full Text] [Related]
18. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
[No Abstract] [Full Text] [Related]
19. Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.
Abbas M; Heitplatz B; Bernemann C; Boegemann M; Trautmann M; Schrader AJ; Wardelmann E; Schlack K
Oncol Lett; 2023 Dec; 26(6):527. PubMed ID: 38020299
[TBL] [Abstract][Full Text] [Related]
20. The differences of regulatory networks between papillary and anaplastic thyroid carcinoma: an integrative transcriptomics study.
Pan Z; Li L; Qian Y; Ge X; Hu X; Zhang Y; Ge M; Huang P
Cancer Biol Ther; 2020 Sep; 21(9):853-862. PubMed ID: 32887540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]